Allergan subpoenaed in Botox investigation

The US department of justice has issued Allergan with a subpoena and requested various documents related to practices involving Botox (botulinum toxin type A).

Used as therapeutic product for the treatment of cervical dystonia, severe hyperhidrosis, strabismus and blepharospasm, the company also produces Botox Cosmetic, which can help to minimise wrinkles.

However, Allergan said it believes the investigation and subpoena regards the “off-label” promotion of Botox in the treatment of headaches. This use of the pharmaceutical is currently at phase III in its clinical trial.

The company said that although physicians are allowed to prescribe drug for uses unapproved by the Food and Drug Administration, Allergan only promotes Botox based on the department’s product labelling.

“Allergan will provide updates as it responds to the subpoena,” it stated. “And will fully cooperate with the US department of justice to satisfactorily address any and all of their questions regarding this matter.”

The safety of Botox has been maintained in previous statements from the company this year.